Literature DB >> 21258041

Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.

Yayoi Shiotsu1, Yasukiyo Mori, Masato Nishimura, Chikako Sakoda, Toshiko Tokoro, Tsuguru Hatta, Noboru Maki, Kumiko Iida, Noriyuki Iwamoto, Toshihiko Ono, Eiko Matsuoka, Noriko Kishimoto, Keiichi Tamagaki, Hiroaki Matsubara, Atsushi Kosaki.   

Abstract

BACKGROUND AND OBJECTIVES: S100A12 is an endogenous receptor ligand for advanced glycation end products. Cardiovascular disease remains a major cause of morbidity and mortality in patients with chronic kidney disease. In this study, we report cross-sectional data on 550 hemodialysis patients and assess the relationship between plasma S100A12 level and cardiovascular disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cross-sectional study of 550 maintenance hemodialysis patients was conducted. We investigated the past history of cardiovascular disease and quantified the plasma level of S100A12 protein in all participants.
RESULTS: Plasma S100A12 level was higher in hemodialysis patients with cardiovascular disease (n=197; 33.8 ± 28.1 ng/ml) than in those without it (n=353; 20.2 ± 16.1 ng/ml; P<0.001). In multivariate logistic regression analysis, the plasma S100A12 level (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.13 to 1.44; P<0.001) was identified as an independent factor associated with the prevalence of cardiovascular disease. The other factors associated with the prevalence of cardiovascular diseases were the presence of diabetes mellitus (OR, 2.81; 95% CI, 1.79 to 4.41; P < 0.001) and high-sensitivity CRP level (OR, 1.02; 95% CI, 1.00 to 1.05; P=0.046). Furthermore, the plasma S100A12 level (OR, 1.30; 95% CI, 1.09 to 1.54; P=0.004) was significantly associated with cardiovascular disease even in hemodialysis patients without diabetes mellitus (n=348).
CONCLUSIONS: These results suggest that the plasma S100A12 protein level is strongly associated with the prevalence of cardiovascular disease in hemodialysis patients.
© 2011 by the American Society of Nephrology

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258041      PMCID: PMC3069361          DOI: 10.2215/CJN.08310910

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

1.  Proinflammatory properties of the human S100 protein S100A12.

Authors:  Z Yang; T Tao; M J Raftery; P Youssef; N Di Girolamo; C L Geczy
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

Review 2.  Inflammatory and atherosclerotic interactions in the depleted uremic patient.

Authors:  P Stenvinkel
Journal:  Blood Purif       Date:  2001       Impact factor: 2.614

Review 3.  Multiple structural states of S100A12: A key to its functional diversity.

Authors:  O V Moroz; G G Dodson; K S Wilson; E Lukanidin; I B Bronstein
Journal:  Microsc Res Tech       Date:  2003-04-15       Impact factor: 2.769

4.  Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis.

Authors:  D Foell; D Kane; B Bresnihan; T Vogl; W Nacken; C Sorg; O Fitzgerald; J Roth
Journal:  Rheumatology (Oxford)       Date:  2003-06-27       Impact factor: 7.580

5.  S100A12 mediates aortic wall remodeling and aortic aneurysm.

Authors:  Marion Hofmann Bowman; Jeannine Wilk; Ahlke Heydemann; Gene Kim; Jalees Rehman; Joseph A Lodato; Jai Raman; Elizabeth M McNally
Journal:  Circ Res       Date:  2009-10-29       Impact factor: 17.367

6.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease.

Authors:  D Foell; T Kucharzik; M Kraft; T Vogl; C Sorg; W Domschke; J Roth
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

7.  S100A12 (EN-RAGE) in monitoring Kawasaki disease.

Authors:  Dirk Foell; Fukiko Ichida; Thomas Vogl; Xianyi Yu; Rui Chen; Toshio Miyawaki; Clemens Sorg; Johannes Roth
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

Review 8.  Cardiovascular mortality in end-stage renal disease.

Authors:  Allan J Collins
Journal:  Am J Med Sci       Date:  2003-04       Impact factor: 2.378

Review 9.  Inflammation in end-stage renal disease: sources, consequences, and therapy.

Authors:  Peter Stenvinkel; Anders Alvestrand
Journal:  Semin Dial       Date:  2002 Sep-Oct       Impact factor: 3.455

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  24 in total

1.  S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.

Authors:  Ling Yan; Liby Mathew; Bijoy Chellan; Brandon Gardner; Judy Earley; Tipu S Puri; Marion A Hofmann Bowman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-22       Impact factor: 8.311

2.  Potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis.

Authors:  Zhang Feng; Zhan Yinchu; Shi Yinsheng; Wu Fengqing; Zhou Xiaoyang; Li Jin; Gao Xiaofei
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 3.  S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.

Authors:  Adam Oesterle; Marion A Hofmann Bowman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

4.  S100/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosis.

Authors:  Marion A Hofmann Bowman; Ann Marie Schmidt
Journal:  Am J Cardiovasc Dis       Date:  2011

Review 5.  Mechanisms and treatment of extraosseous calcification in chronic kidney disease.

Authors:  Markus Ketteler; Hansjörg Rothe; Thilo Krüger; Patrick H Biggar; Georg Schlieper
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

6.  Common Aging Signature in the Peripheral Blood of Vascular Dementia and Alzheimer's Disease.

Authors:  Hongbo Luo; Guangchun Han; Jiajia Wang; Fan Zeng; Yuanming Li; Shaoju Shao; Fuhai Song; Zhouxian Bai; Xing Peng; Yan-Jiang Wang; Xiangqun Shi; Hongxing Lei
Journal:  Mol Neurobiol       Date:  2015-06-23       Impact factor: 5.590

7.  Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.

Authors:  Ling Yan; Marion A Hofmann Bowman
Journal:  Inflamm Cell Signal       Date:  2014

8.  Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease.

Authors:  Insa M Schmidt; Suraj Sarvode Mothi; Parker C Wilson; Ragnar Palsson; Anand Srivastava; Ingrid F Onul; Zoe A Kibbelaar; Min Zhuo; Afolarin Amodu; Isaac E Stillman; Helmut G Rennke; Benjamin D Humphreys; Sushrut S Waikar
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-10       Impact factor: 8.237

9.  Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial.

Authors:  Steven Rosenberg; Michael R Elashoff; Hsiao D Lieu; Bradley O Brown; William E Kraus; Robert S Schwartz; Szilard Voros; Stephen G Ellis; Ron Waksman; John A McPherson; Alexandra J Lansky; Eric J Topol
Journal:  J Cardiovasc Transl Res       Date:  2012-03-07       Impact factor: 4.132

10.  Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan.

Authors:  Yayoi Shiotsu; Yasukiyo Mori; Masato Nishimura; Tsuguru Hatta; Naoki Imada; Noboru Maki; Kumiko Iida; Noriyuki Iwamoto; Eiko Matsuoka; Keiichi Tamagaki; Atsushi Kosaki
Journal:  BMC Nephrol       Date:  2013-01-16       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.